naptumomab estafenatox
glembatumumab
volociximab
cemiplimab
abagovomab
brolucizumab
amlitelimab
sibrotuzumab
tislelizumab
olaratumab
etaracizumab
pidilizumab
gevokizumab
zalutumumab
ravulizumab
inotuzumab ozogamicin
fontolizumab
ozogamicin
bivatuzumab
-lim-
intrabody
olendalizumab
lexatumumab
-toxa-
ipilimumab
antimonoclonal
-zumab
immunochemiluminometric
rapid antigen test
tabalumab
tigatuzumab
agonistic monoclonal antibody
dalotuzumab
durvalumab
Forssman antibody
heterophile antibody
microlymphocytotoxicity
heterophil antibody
brodalumab
talacotuzumab
immunostrip
lenzilumab
immunofluorescence
immunolabeling
siltuximab
antinucleosome
ocrelizumab
bectumomab
-o-
robatumumab